VALUE OF POLYMORPHISMS rs759853 and rs9640883 AKR1B1 GENE AT THE DIABETIC RETINOPATHY

Authors

  • S.Yu. Mogilevskiy National Medical Academy of Postgraduate Education named after P.L. Shupyk of the Ministry of Public Health of Ukraine
  • L.I. Denysyuk Kyiv City Clinical Ophthalmologacal Hospital “Eye Microsurgery Center” of the Ministry of Public Health of Ukraine Kyiv, Ukraine
  • O.V. Bushueva Lviv National Medical University named after Danylo Halytskiy of the Ministry of Public Health of Ukraine Lviv, Ukraine

DOI:

https://doi.org/10.22141/2309-8147.3.1.2015.173112

Keywords:

diabetes mellitus 2 types, diabetic retinopathy, gene AKR1B1 polymorphism, rs759853, rs9640883

Abstract

Determination of the importance of AKR1B1 gene polymorphisms rs759853 and rs9640883 at the diabetic retinopathy became an object of this research. In 39 patients with diabetes mellitus 2 types and diabetic retinopathy it was determined gene polymorphisms by method of polymerase chain reaction in real time. It was shown that both polymorphisms were connected with compensation status of diabetes. Existence of the minor genotype AA of rs759853 promoted the bigger retina central thickness that could point to strengthening of macular edema owing to bigger intracellular sorbitol accumulation. Carriers of the minor allele A rs9640883 (genotypes GA and AA) were operated earlier on the average of six years. This points to bigger progressing of retina pathological process in cases with allele A presence.

References

Щулькин А.В. Генетические маркеры развития диабетической ретинопатии / А.В. Щулькин, А.В. Колесников, О.И. Баренина, А.А. Никифоров // Фундаментальные исследования. – 2014. – № 4–2. – С. 411–414.

Abhary S. A systematic meta-analysis of genetic association studies for diabetic retinopathy //S. Abhary, A.W. Hewitt, K.P. Burdon, J.E. Craig // Diabetes. – 2009. – Vol. 58. – P. 2137–2147.

Abhary S. Aldose reductase gene polymorphisms and diabetic retinopathy susceptibility /S. Abhary, K.P. Burdon, K.J. Laurie et al. // Diabetes Care. – 2010. – Vol. 33(8). – P. 834–836.

Asnaghi V. A role for the polyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat / V. Asnaghi, C. Gerhardinger, T. Hoehn et al. // Diabetes. – 2003. – Vol. 52(2). P. 506–511.

Chung S.S. Aldose reductase in diabetic microvascular complications / S.S. Chung, S.K. Chung // Curr Drug Targets. 2005 Jun;6(4):475–86.

Dagher Z. Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy / Z. Dagher, Y.S. Park, V. Asnaghi et al. // Diabetes. – 2004. – Vol. 53(9). – P. 2404–2411.

Jane Z. Kuo. Challenges in elucidating the genetics of diabetic retinopathy / Jane Z. Kuo, Tien Y. Wong, Jerome I. Rotter // JAMA. Ophthalmol. – 2014. – Vol. 132(1). – P. 96–107.

Joanna M. Tarr. Pathophysiology of diabetic retinopathy / Joanna M. Tarr, Kirti Kaul, Mohit Chopra et al. // ISRN Ophthalmol. – 2013. – 2013. – P. 343–560.

Lorenzi M. The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive and resilient / M. Lorenzi // Exp Diabetes Res. 2007;2007:61038. doi: 10.1155/2007/61038.

Obrosova I.G. Aldose reductase polyol inhibitors for diabetic retinopathy / I.G. Obrosova, P.F. Kador // Curr Pharm Biotechnol. – 2011. – Vol. 12(3). – P. 373–385.

Published

2015-02-01

Issue

Section

Clinical Ophthalmology